Sugi Predict

Sugi Predict / Compounds / SCHEMBL967058

SCHEMBL967058

SCHEMBL967058

NNC(=O)CC1CCCC1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.57
▸ HPGD P15428 3/20 0.57
▸ EPHX1 P07099 1/20 0.57
▸ RAB9A P51151 5/20 0.47
▸ NPC1 O15118 5/20 0.47
▸ EPHX2 P34913 4/20 0.47
▸ AAK1 Q2M2I8 1/20 0.42
▸ POLB P06746 2/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ ALPL P05186 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14606389 0.98 KMT2A (0.61) KMT2AHPGDEPHX1RAB9ANPC1
SCHEMBL14456383 0.98 KMT2A (0.61) KMT2AHPGDEPHX1RAB9ANPC1
SCHEMBL2825190 0.98 KMT2A (0.61) KMT2AHPGDEPHX1RAB9ANPC1
SCHEMBL23624679 0.98 KMT2A (0.61) KMT2AHPGDEPHX1RAB9ANPC1
SCHEMBL12467463 0.98 KMT2A (0.61) KMT2AHPGDEPHX1RAB9ANPC1
SCHEMBL24235893 0.98 KMT2A (0.61) KMT2AHPGDEPHX1RAB9ANPC1
SCHEMBL21378703 0.95 — —
SCHEMBL2828533 0.90 — —
SCHEMBL8746838 0.80 TNKS2 (0.42) KMT2AHPGDEPHX1RAB9ANPC1
SCHEMBL7450596 0.80 EPHX1 (0.53) KMT2AHPGDEPHX1EPHX2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3541802-B1 ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR AMGEN INC (US) 2025-01-01 — — EP disclosed
EP-3626699-B1 SSAO INHIBITOR SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) 2023-07-12 — — EP disclosed
US-11191762-B2 Alkyl substituted triazole compounds as agonists of the APJ Receptor AMGEN INC. (US) 2021-12-07 — — US disclosed
US-20210198220-A1 SSAO INHIBITOR SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) 2021-07-01 — — US disclosed
US-11001563-B2 SSAO inhibitor SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) 2021-05-11 — — US disclosed
US-20200115352-A1 SSAO INHIBITOR SHANDONG DANHONG PHARMACEUTICAL CO., LTD. 2020-04-16 — — US disclosed
EP-3626699-A1 SSAO INHIBITOR Shandong Danhong Pharmaceutical Co., Ltd. (CN) 2020-03-25 — — EP disclosed
US-20190290647-A1 ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR AMGEN INC. (US) 2019-09-26 — — US disclosed
US-8962843-B2 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors CUBIST PHARMACEUTICALS, INC. (US) 2015-02-24 — — US disclosed
US-8962844-B2 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors CUBIST PHARMACEUTICALS, INC. (US) 2015-02-24 — — US disclosed
US-20130296291-A1 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME LLC 2013-11-07 — — US disclosed
US-20130296293-A1 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME LLC 2013-11-07 — — US disclosed
US-20130296292-A1 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME LLC 2013-11-07 — — US disclosed
US-20130296290-A1 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME LLC 2013-11-07 — — US disclosed
US-20110003794-A1 Naphthyridine Integrase Inhibitors GSK LLC 2011-01-06 — — US disclosed
US-7812016-B2 Naphthyridine integrase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2010-10-12 — — US disclosed
EP-1622615-A4 NAPHTHYRIDINE INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2009-02-18 — — EP disclosed
US-20070142365-A1 Naphthyridine integrase inhibitors GSK LLC 2007-06-21 — — US disclosed
EP-1622615-A2 NAPHTHYRIDINE INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2006-02-08 — — EP disclosed
WO-2004101512-A2 NAPHTHYRIDINE INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-11-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11001563-B2 SSAO inhibitor SSB, ASAH2, AOX1 KMT2A 4204/4885HPGD 601/4885EPHX1 872/4885
US-20130296293-A1 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS BTD, BLVRB, PEPD KMT2A 3510/4885HPGD 246/4885EPHX1 914/4885
US-20110003794-A1 Naphthyridine Integrase Inhibitors PCNA, SAMHD1, NTPCR KMT2A 1772/4885HPGD 1538/4885EPHX1 3692/4885
US-20210198220-A1 SSAO INHIBITOR SSB, ASAH2, AOX1 KMT2A 4204/4885HPGD 601/4885EPHX1 872/4885
US-11191762-B2 Alkyl substituted triazole compounds as agonists of the APJ Receptor AGTR1, AGTR2, APLNR KMT2A 3639/4885HPGD 2166/4885EPHX1 3160/4885
US-20070142365-A1 Naphthyridine integrase inhibitors PCNA, SAMHD1, NTPCR KMT2A 1772/4885HPGD 1538/4885EPHX1 3692/4885
US-20130296290-A1 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS BTD, BLVRB, PEPD KMT2A 3510/4885HPGD 246/4885EPHX1 914/4885
US-20190290647-A1 ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR AGTR1, AGTR2, APLNR KMT2A 3639/4885HPGD 2166/4885EPHX1 3160/4885
US-20130296291-A1 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS BTD, BLVRB, PEPD KMT2A 3510/4885HPGD 246/4885EPHX1 914/4885
US-20200115352-A1 SSAO INHIBITOR SSB, ASAH2, AOX1 KMT2A 4204/4885HPGD 601/4885EPHX1 872/4885
US-20130296292-A1 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS BTD, BLVRB, PEPD KMT2A 3510/4885HPGD 246/4885EPHX1 914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.